Angiogenesis in prostate cancer: onset, progression and imaging

What's known on the subject? and What does the study add?

[1]  M Buyse,et al.  Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. , 1997, The American journal of pathology.

[2]  V. Barbieri,et al.  Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. , 2009, Carcinogenesis.

[3]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[4]  Craig S. Levin,et al.  Primer on molecular imaging technology , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  A. Hanlon,et al.  Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. , 2001, Urology.

[6]  M. Ittmann,et al.  The role of fibroblast growth factors and their receptors in prostate cancer. , 2004, Endocrine-related cancer.

[7]  P. Stattin,et al.  Vascular density is a predictor of cancer‐specific survival in prostatic carcinoma , 1997, The Prostate.

[8]  David Cosgrove,et al.  Imaging of perfusion using ultrasound , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Clare Allen,et al.  Dynamic contrast enhanced MRI in prostate cancer. , 2007, European journal of radiology.

[10]  Massimo Mischi,et al.  Contrast-Ultrasound Diffusion Imaging for Localization of Prostate Cancer , 2011, IEEE Transactions on Medical Imaging.

[11]  David Cosgrove,et al.  Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. , 2008, European urology.

[12]  Mario Marengo,et al.  Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  P. Carroll,et al.  Multiparametric magnetic resonance imaging in prostate cancer: present and future , 2008, Current opinion in urology.

[14]  François Tranquart,et al.  Ultrasound Molecular Imaging of VEGFR2 in a Rat Prostate Tumor Model Using BR55 , 2010, Investigative radiology.

[15]  Y. Yamabe,et al.  Androgen-Dependent Gene Expression of Prostate-Specific Antigen Is Enhanced Synergistically by Hypoxia in Human Prostate Cancer Cells , 2007, Molecular Cancer Research.

[16]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[17]  Peter Carmeliet,et al.  Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.

[18]  V. Laudone,et al.  Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. , 1998, Urology.

[19]  D. Cosgrove,et al.  Angiogenesis imaging in the management of prostate cancer , 2005, Nature Clinical Practice Urology.

[20]  Thorsten Schlomm,et al.  Prognostic value of microvessel density in prostate cancer: a tissue microarray study , 2010, World Journal of Urology.

[21]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[22]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[23]  K. Shinohara,et al.  The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer , 2010, BJU international.

[24]  Hessel Wijkstra,et al.  Microvessel Density: Correlation between Contrast Ultrasonography and Histology of Prostate Cancer , 2001, European Urology.

[25]  Namkug Kim,et al.  Functional MR imaging of prostate cancer. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[26]  Peter L Choyke,et al.  Imaging prostate cancer: a multidisciplinary perspective. , 2007, Radiology.

[27]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[28]  M. Conti.  Focus on time-of-flight PET: the benefits of improved time resolution , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Robert E Lenkinski,et al.  Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. , 2007, Radiology.

[30]  E. Sage,et al.  PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors , 1994, The Journal of cell biology.

[31]  R. Montironi,et al.  Vascular endothelial growth factor expression and capillary architecture in high‐grade PIN and prostate cancer in untreated and androgen‐ablated patients , 2000, The Prostate.

[32]  R. Autorino,et al.  Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease , 2005, Prostate Cancer and Prostatic Diseases.

[33]  C. Stief,et al.  Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. , 2011, Urologic oncology.

[34]  C. Dinney,et al.  Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. , 2000, Cancer research.

[35]  M. Hendrix,et al.  Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma , 2003, Nature Reviews Cancer.

[36]  K Hamamoto,et al.  [Scintillation camera]. , 1967, Saishin igaku. Modern medicine.

[37]  M. Centrella,et al.  Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis. , 1996, The Journal of clinical investigation.

[38]  A. Neugut,et al.  Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. , 1999, Urology.

[39]  Tatiana V. Petrova,et al.  Lymphangiogenesis in development and human disease , 2005, Nature.

[40]  H. Huisman,et al.  Standardized Threshold Approach Using Three-Dimensional Proton Magnetic Resonance Spectroscopic Imaging in Prostate Cancer Localization of the Entire Prostate , 2007, Investigative radiology.

[41]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[42]  H. Jadvar.  Prostate Cancer : PET with 18 F-FDG , 18 For 11 C-Acetate , and 18 For 11 C-Choline , 2010 .

[43]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[44]  C. Dinney,et al.  The role of angiogenesis in prostate and other urologic cancers: a review. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[45]  Andrew J. Vickers,et al.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.

[46]  Victor E Reuter,et al.  Prostate-specific membrane antigen expression in regeneration and repair , 2008, Modern Pathology.

[47]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[48]  A. Bergh,et al.  Role of transforming growth factor‐β1 in prostate cancer , 2001 .

[49]  Ferdinand Frauscher,et al.  Detection of prostate carcinoma with contrast‐enhanced sonography using intermittent harmonic imaging , 2005, Cancer.

[50]  B. Wouters,et al.  Hypoxia signalling through mTOR and the unfolded protein response in cancer , 2008, Nature Reviews Cancer.

[51]  G. Semenza,et al.  Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. , 2004, Cancer detection and prevention.

[52]  Nikolaos Kavantzas,et al.  Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer , 2001, Virchows Archiv.

[53]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[54]  G. Farhat,et al.  Diagnostic ultrasound Imaging : Inside out , 2004 .

[55]  M. Reiser,et al.  Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. , 2007, AJR. American journal of roentgenology.

[56]  Massimo Mischi,et al.  Novel contrast-enhanced ultrasound imaging in prostate cancer , 2011, World Journal of Urology.

[57]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[59]  W. Horninger,et al.  Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection , 2010, European Radiology.

[60]  J J de la Rosette,et al.  Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia. , 2001, Urology.

[61]  Study of matrix metalloproteinases and their inhibitors in prostate cancer , 2010, British Journal of Cancer.

[62]  M. Hendrix,et al.  Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. , 2007, The American journal of pathology.

[63]  F. Wamunyokoli,et al.  A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. , 2006, Cancer research.

[64]  C. Kim,et al.  High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. , 2010, AJR. American journal of roentgenology.

[65]  M. Brawer,et al.  Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.

[66]  T Okada,et al.  Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. , 2001, Urology.

[67]  H. Schlemmer,et al.  Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? , 2004, European Radiology.

[68]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[69]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[70]  M. Blake,et al.  Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers. , 2001, Radiology.

[71]  Janet Rossant,et al.  Endothelial cells and VEGF in vascular development , 2005, Nature.

[72]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[73]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[74]  H. Dvorak,et al.  Vascular permeability, vascular hyperpermeability and angiogenesis , 2008, Angiogenesis.

[75]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[76]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[77]  A. Partin,et al.  Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate , 1997, Cancer.

[78]  G. Gualdi,et al.  Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging , 2006, Abdominal Imaging.

[79]  J. Rak,et al.  Host microenvironment in breast cancer development: Inflammatory and immune cells in tumour angiogenesis and arteriogenesis , 2003, Breast Cancer Research.

[80]  Nico de Jong,et al.  Ultrasonic characterization of ultrasound contrast agents , 2009, Medical & Biological Engineering & Computing.

[81]  Dai Fukumura,et al.  Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre‐Clinical Models , 2010, Microcirculation.

[82]  H. Jadvar.  Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline , 2011, The Journal of Nuclear Medicine.

[83]  M. Janicek,et al.  Tumor angiogenesis as a prognostic factor in ovarian carcinoma , 1997, Cancer.

[84]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[85]  N de Jong,et al.  Ultrasound contrast imaging: current and new potential methods. , 2000, Ultrasound in medicine & biology.

[86]  R. Friesel,et al.  Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[88]  Samir S. Taneja,et al.  ProstaScint® Scan: Contemporary Use in Clinical Practice , 2004 .

[89]  P. Kantoff,et al.  Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. , 2001, Cancer research.

[90]  P. Stricker,et al.  Growth factor involvement in progression of prostate cancer. , 1998, Clinical chemistry.

[91]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[92]  F. Frauscher,et al.  Prostate: high-frequency Doppler US imaging for cancer detection. , 2002, Radiology.

[93]  F Forsberg,et al.  Ultrasonic characterization of the nonlinear properties of contrast microbubbles. , 2000, Ultrasound in medicine & biology.

[94]  R K Jain,et al.  Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[95]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[96]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[97]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[98]  Hessel Wijkstra,et al.  The value of dynamic contrast enhanced power Doppler ultrasound imaging in the localization of prostate cancer. , 2003, European urology.

[99]  F. Vizoso,et al.  Study of matrix metalloproteinases and their inhibitors in breast cancer , 2007, British Journal of Cancer.

[100]  B. Krause,et al.  Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. , 2013, Urologic oncology.

[101]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[102]  N. Lunet,et al.  VEGF and prostatic cancer: a systematic review , 2010, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[103]  Mithat Gonen,et al.  Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  B. Carey,et al.  Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.

[105]  Lars Hoff,et al.  Acoustic Characterization of Contrast Agents for Medical Ultrasound Imaging , 2001, Springer Netherlands.

[106]  Roman Zachoval,et al.  Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer , 2008, International journal of urology : official journal of the Japanese Urological Association.

[107]  F. Forsberg,et al.  Contrast enhanced ultrasound flash replenishment method for directed prostate biopsies. , 2007, The Journal of urology.

[108]  A R Jayaweera,et al.  Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. , 1998, Circulation.

[109]  J. Lawler,et al.  The cell biology of thrombospondin-1. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[110]  S. Biesterfeld,et al.  Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue , 2003, Prostate Cancer and Prostatic Diseases.

[111]  P. Carroll,et al.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.

[112]  T. Krouskop,et al.  Elastic Moduli of Breast and Prostate Tissues under Compression , 1998, Ultrasonic imaging.

[113]  M. Mischi,et al.  Angiogenesis imaging by spatiotemporal analysis of ultrasound contrast agent dispersion kinetics , 2012, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[114]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[115]  伊藤 壽一,et al.  PET(Positron Emission Tomography) , 1997 .

[116]  David Cosgrove,et al.  Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel , 2012, BJU international.

[117]  M. Frydenberg,et al.  Prostatic cancer: role of color Doppler imaging in transrectal sonography. , 1998, AJR. American journal of roentgenology.

[118]  Emilio Quaia,et al.  Microbubble ultrasound contrast agents: an update , 2007, European Radiology.

[119]  M. Terris,et al.  Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. , 2001, Urology.

[120]  N. Kyprianou,et al.  Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. , 2008, Endocrine-related cancer.

[121]  Cher Heng Tan,et al.  Diffusion weighted imaging in prostate cancer , 2011, European Radiology.

[122]  E. Halpern,et al.  Contrast-enhanced ultrasound imaging of prostate cancer. , 2006, Reviews in urology.

[123]  Clare Allen,et al.  How good is MRI at detecting and characterising cancer within the prostate? , 2006, European urology.

[124]  Nathalie Lassau,et al.  Methodology for quantifying interactions between perfusion evaluated by DCE-US and hypoxia throughout tumor growth. , 2007, Ultrasound in medicine & biology.

[125]  P. Humphrey,et al.  Gleason grading and prognostic factors in carcinoma of the prostate , 2004, Modern Pathology.

[126]  L. Chung,et al.  Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. , 2005, The Journal of urology.

[127]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[128]  C. Dinney,et al.  Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[129]  C. Gallou-Kabani,et al.  Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. , 2011, Cancer research.

[130]  Yong Li,et al.  Angiogenesis as a strategic target for prostate cancer therapy , 2010, Medicinal research reviews.

[131]  T. Wheeler,et al.  Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.